Get the Stockscreener App
17.71
5.23%
0.88
Sarepta Therapeutics Inc stock is traded at $17.71, with a volume of 1.86M.
It is up +5.23% in the last 24 hours and down -14.53% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$16.83
Open:
$16.96
24h Volume:
1.86M
Relative Volume:
0.63
Market Cap:
$1.87B
Revenue:
$2.18B
Net Income/Loss:
$-64.32M
P/E Ratio:
-18.37
EPS:
-0.9641
Net Cash Flow:
$91.18M
1W Performance:
-2.75%
1M Performance:
-14.53%
6M Performance:
-18.50%
1Y Performance:
-20.23%
1-Day Range:
$16.61
$17.95
1-Week Range:
$16.37
$18.52
52-Week Range:
$14.68
$24.68
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.71 | 1.87B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Top Research Reports for SpaceX, Dell & KLA Corp. - Zacks Investment Research
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
A treatment was linked to better movement over 2 years in boys ages 8 to 12 with Duchenne - Stock Titan
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
IRWD Stock Price, Quote & News - Syfe
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
AQST Stock Price, Quote & News - Syfe
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com Canada
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook - Investing.com India
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com UK
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com Nigeria
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com India
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Business Wire
Why is Sarepta Therapeutics stock sliding today? - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Landscape with Innovative Therapies - DirectorsTalk Interviews
Sarepta Therapeutics Faces Investor Investigations – 8-5 - stl.news
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report? - Yahoo Finance
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Potential Upside In Biotech Amidst Revenue Challenges - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - Sahm
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - simplywall.st
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution - Seeking Alpha
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’ - Stocktwits
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value - Yahoo Finance
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - Business Wire
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sarepta Therapeutics Inc Stock (SRPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHEN MAYO | Director |
Mar 12 '26 |
Proposed Sale |
17.02 |
7,239 |
123,175 |
0 |
| Estepan Ian Michael | Chief Operating Officer |
Feb 26 '26 |
Option Exercise |
13.71 |
7,450 |
102,140 |
200,750 |
| Nicaise Claude | Director |
Jan 29 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
38,312 |
| BEHRENS M KATHLEEN | Director |
Jan 27 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
203,976 |
| Estepan Ian Michael | Chief Operating Officer |
Dec 16 '25 |
Sale |
22.31 |
13,187 |
294,202 |
193,300 |
| IAN M ESTEPAN | Officer |
Dec 16 '25 |
Proposed Sale |
22.31 |
13,187 |
294,145 |
0 |
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):